The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. Issue 16 (November 2015)

• Record Type: Journal Article
• Authors: Barrios, Carlos H.; Blackstein, Martin E.; Blay, Jean-Yves; Casali, Paolo G.; Chacon, Matias; Gu, Jin; Kang, Yoon-Koo; Nishida, Toshirou; Purkayastha, Das; Woodman, Richard C.; Reichardt, Peter
• Is Part Of: European journal of cancer. Volume 51:Issue 16(2015:Nov.)
• Page Start: 2423
• Page End: 2433
• Publication Date: 2015-11
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2015.07.010
• Languages: English
• ISSNs: 0959-8049

Abstract

<abstract xml:lang="en" abstract-type="author" id="ab005"> <title id="st005">Abstract</title> <sec> <title id="st010">Background</title> <p id="sp0005">Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal sarcomas. This global, prospective registry followed patients with advanced or localised GIST (2007–2011).</p> </sec> <sec> <title id="st015">Methods</title> <p id="sp0010">Current and evolving diagnostics, treatments and outcome measures in patients with GIST were assessed. Eligible patients were diagnosed with advanced or localised GIST within 15 months of registry entry. No treatment plan was prescribed, and no visit schedule was mandated. Treating physicians recorded patient information, including tumour response, diagnostic methods, medications, surgeries performed, mutation status and adverse events leading to dose/medication changes. Survival outcomes were estimated using the Kaplan–Meier method. Other data were analysed using descriptive statistics.</p> </sec> <sec> <title id="st020">Results</title> <p id="sp0015">The registry included 1663 patients (advanced GIST, <italic>n</italic> = 1095; localised GIST, <italic>n</italic> = 537). Medications (e.g. tyrosine kinase inhibitor use and dosing), disease progression or recurrence and physician assessment of response to treatment in registry patients were consistent with controlled trials and prevailing clinical recommendations. In advanced GIST, estimated 30-month progression-free survival (PFS) (59.8%) and overall survival (OS) (82.7%) were higher than results from previously reported trials (≈40% and ≈70%, respectively). Consistent with treatment guidelines, the most common initial treatments were imatinib for advanced GIST, and complete surgical resection for localised GIST. Computed tomography scans were the most common imaging technique used at diagnosis and follow-up. Mutation analysis was performed at diagnosis in only 15.3% and 14.5% of patients with advanced and localised GIST, respectively.</p> </sec> <sec> <title id="st025">Conclusions</title> <p id="sp0020">In this real-world GIST registry, patients with advanced GIST were treated with imatinib and patients with localised GIST received surgical resection, in accordance with prevailing clinical recommendations.</p> </sec> </abstract>